A humanized monoclonal antibody to CXCR4, ulocuplumab (BMS-936564), has been tested in early phase trials and was well tolerated with some demonstrated clinically efficacy in multiple myeloma patients [312]. Here, CXCR4 is linked to plasma cell myeloma.